Skip to main content
. Author manuscript; available in PMC: 2011 Aug 1.
Published in final edited form as: Cancer Res. 2010 Jul 20;70(15):6303–6312. doi: 10.1158/0008-5472.CAN-10-1022

Figure 3. Cell toxicity analysis of human astrocytes and glioblastoma cells treated with IONPs.

Figure 3

A., Human astrocytes were treated with control vehicle (serum-free medium) or IONPs. at 0, 1, 2, and 3 days. No significant toxicity was found with IONP treatment of human astrocytes (P < 0.001). Cell toxicity analysis of human glioblastoma cells (B. U87-MG and C. U87ΔEGFRvIII) after treatment by control vehicle (PBS), IONPs, EGFRvIIIAb, and EGFRvIIIAb-IONPs at 0, 1, and 3 days. A significant decrease in cell survival was found in glioblastoma cells treated by IONPs, EGFRvIIIAb, and EGFRvIIIAb-IONPs at 3 days (P<0.001).